- BofA Securities has upgraded BioNTech SE BNTX and maintains a $239 price target.
- The analyst views the current valuation as an attractive entry opportunity citing several near-term opportunities, including an expanded opportunity for the COVID vaccine and de-risking of the growing oncology pipeline.
- Recent update on Moderna Inc MRNA / Merck & Co Inc MRK on personalized cancer vaccine for melanoma might provide POC validation ahead of BNT122’s readout in combo with Keytruda in 1L advanced melanoma in 1H23.
- The analyst writes that the mRNA-based flu/COVID combo vaccine represents an attractive opportunity, with positive data probably next year could represent additional upside.
- Amid lower demand for vaccines, BofA lowered its COVID revenues to BNTX to €8 billion in 2023 (down from €17 billion in ’22) and assumed a more conservative stance near term).
- The oncology pipeline represents the next leg of growth for the company, and the analyst sees potential for an upside as these programs mature. iNeST and FixVac currently contribute $33/share to BofA valuation.
- Price Action: BNTX shares are down 2.93% at $180.59 on the last check Thursday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in